ESMO 2019 Congress | OncologyPRO

Abstract 1402

Background

Neoadjuvant chemotherapy is promising to improve the survival of locally advanced gastric cancer. However, optimal regimen and duration of treatment have not been established. We previously reported the primary results of COMPASS-D trial (ASCO-GI 2019). Herein, we report the results of subgroup analyses of efficacy by baseline disease characteristics and demographics.

Methods

Patients with M0 and either T4 or T3 in case of junctional cancer or schirrhous type received 2 or 4 courses of cisplatin (60 mg/m2 at day 8) / S-1 (80 mg/m2 for 21 days with 1 week rest) or docetaxel (40 mg/m2 at day 1) / cisplatin (60 mg/m2 at day 1) / S-1 (80 mg/m2 for 14 days with 2 weeks rest) as neoadjuvant chemotherapy. Then, patients underwent D2 gastrectomy and adjuvant S-1 chemotherapy for 1 year. The primary endpoint was 3-year overall survival. Subgroup analysis was performed in each regimen (CS vs DCS) and duration (2 vs 4 courses), stratified by age, gender, esophageal invasion, macroscopic type, histological type, cT, and cN.

Results

Between Oct 2011 and Sep 2014, 132 patients were assigned to CS (n = 66; 33 in 2-courses and 33 in 4-courses) and DCS (n = 66; 33 in 2-courses and 33 in 4-courses). The 3-year OS was 58.1% in 2-courses CS, 58.1% in 4-courses CS, 48.5% in 2-courses DCS, and 71.9% in 4-courses DCS. Subgroup analyses were summarized in the table.Table:

778P

Subgroup	HR of 4-sourses (95%CI)	HR of DCS (95%CI)
Overall	0.77 (0.43-1.22)	0.80 (0.48-1.34)
Age < 70 y.o.	0.82 (0.45-1.52)	0.88 (0.48-1.62)
Age = > 70 y.o.	0.49 (0.17-1.39)	0.68 (0.26-1.76)
Male	0.53 (0.27-1.05)	0.81 (0.42-1.54)
Female	1.22 (0.51-2.90)	0.79 (0.33-1.87)
Esophageal invasion-	0.72 (0.40-1.31)	0.71 (0.39-1.27)
Esophageal invasion+	0.73 (0.24-2.17)	1.06 (0.36-3.16)
Schirrhous or large Type3	0.47 (0.22-1.00)	0.82 (0.41-1.63)
Non schirrous or large Type3	0.74 (0.23-2.41)	0.50 (0.13-1.87)
Differentiated	0.37 (0.08-1.66)	0.38 (0.09-1.71)
Undiffirentiated	0.66 (0.32-1.36)	1.24 (0.63-2.43)
cT3 or T4a	0.66 (0.38-1.17)	0.76 (0.44-1.32)
cT4b	N/A	2.33 (0.26-21.4)
cN0	0.77 (0.32-1.86)	0.74 (0.31-1.80)
cN +	0.66 (0.34-1.27)	0.87 (0.46-1.66)

Conclusions

The DCS regimen and duration 4-courses showed a beneficial tendency as a neoadjuvant setting regardless of disease characteristics and demographics. The 4-courses DCS is widely applicable to future phase III study to confirm of neoadjuvant chemotherapy for locally advanced gastric cancer.

Clinical trial identification

UMIN000006378.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

The Nongovermental Organization, Kanagawa Standard Anti-cancer Therapy Support System.

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

29 Sep 2019